Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
neuroendocrine tumor 3 endocrinologydiseases
carcinoid 13 endocrinologydiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
carcinoid 2402 (MNETs) are recognized for the ability to secrete serotonin and are associated with the development of carcinoid syndrome (CS). Considered as rare neoplasm traditionally, the incidence of MNETs has gone through a
carcinoid 12203 second primary resection2.0%0%Subgroup analysisDifferent patient characteristics such as presence of carcinoid syndrome, Ki67 status/tumor staging could affect the results. Operation strategies also contribute to
carcinoid 18961 metastasis includes: primary tumor burden related death, liver metastasis related death, death related to carcinoid syndrome, treatment related death, and death irrelevant to tumor, which is approximately 40-50% due
carcinoid 19272 causes of tumor-related death for MNETs were tumor burden(47.7%), small bowel obstruction(13.6%) and carcinoid heart disease (11.4%). Ahmed et al. [[14]] showed the most frequent disease-specific death causes for
carcinoid 19473 causes for liver metastatic MNETs to be tumor progression (48%), small bowel obstruction (15%), and carcinoid heart disease (7%).Tumor burden from liver metastasis is a main death cause for MNETs According to Givi
carcinoid 21672 resection and instead led to post-surgical intestinal adhesion.Another important death-causing factor is carcinoid syndrome. Death caused by carcinoid syndrome is mainly due to carcinoid heart disease (CHD) and patients
carcinoid 21708 post-surgical intestinal adhesion.Another important death-causing factor is carcinoid syndrome. Death caused by carcinoid syndrome is mainly due to carcinoid heart disease (CHD) and patients die of progressive heart failure
carcinoid 21744 important death-causing factor is carcinoid syndrome. Death caused by carcinoid syndrome is mainly due to carcinoid heart disease (CHD) and patients die of progressive heart failure in most cases. The presence of CHD
carcinoid 22467 in the above 8 studies that resection of primary tumor resulted in better survival in patients with carcinoid syndrome. In the research carried out by S. Pusceddu et al. [[18]], all patients enrolled had liver
carcinoid 22598 research carried out by S. Pusceddu et al. [[18]], all patients enrolled had liver metastatic NETs with carcinoid syndrome. The MOS was 141 months versus 37 months for primary resected and unresected group. The poor
carcinoid 22745 versus 37 months for primary resected and unresected group. The poor overall survival for patients with carcinoid syndrome was confirmed by Strosberg et al. [[13]], who demonstrated a MOS of 53 months regardless of
carcinoid 24006 patient information that could affect prognosis, including tumor grade, presence of symptoms, presence of carcinoid heart disease, level of 5-HIAA etc. and survival analysis for primary tumor resection among these subgroups.
carcinoid 27315 follow-up time and year of publication, types of surgery; sex, age, histology, biochemical markers and carcinoid symptoms; OS, PFS, cause of death (treatment-related mortality etc.) and symptom relief.Quality assessmentStudy
neuroendocrine tumor 1176 ChinaPublication date (collection): 3/2017Publication date (epub): 12/2016AbstractBackgroundTreatment for midgut neuroendocrine tumor patients with unresectable liver metastasis has long been a controversial issue. This system review
neuroendocrine tumor 2131 death and symptom relief.ConclusionsCurrent evidence supports resection of primary tumor for midgut neuroendocrine tumor patients with liver metastases, but randomized controlled trials are required to reach a final conclusion.INTRODUCTIONMidgut
neuroendocrine tumor 2277 metastases, but randomized controlled trials are required to reach a final conclusion.INTRODUCTIONMidgut neuroendocrine tumor s (MNETs) are recognized for the ability to secrete serotonin and are associated with the development

You must be authorized to submit a review.